What Wegovy research tells us — and what it doesn't

You've read the headlines. Here's what the trials actually measured.

Perhaps you've seen a newspaper graphic showing 15% weight loss and wondered whether that figure was cherry-picked or typical. It comes from STEP 1, the largest of the four STEP trials, which followed nearly 2,000 adults with obesity or overweight plus at least one weight-related condition over 68 weeks. Participants weren't passive: they also received lifestyle counselling. The 15% average figure is a population mean (roughly half of participants lost more, half less) and it was measured against a placebo group that lost around 2.4%, confirming the medicine's independent effect beyond behavioural support alone.

STEP 2 focused specifically on people with type 2 diabetes alongside obesity, where average weight loss was lower (around 10%), reflecting how that condition affects metabolic response. STEP 3 added intensive behavioural therapy on top of the injection, producing higher average losses still. The programme as a whole is unusually thorough; it's one of the reasons NICE's appraisal in TA875 took the evidence seriously enough to recommend the medicine within the NHS, subject to specialist oversight and a two-year treatment limit under that pathway.

Semaglutide research has continued well beyond the original STEP results, and our semaglutide peptide research page explains how the molecule's design underpins these findings. The SELECT trial demonstrated a reduction in major cardiovascular events in eligible adults. More recently, on 3 July 2026, the MHRA granted conditional approval for Wegovy in MASH, a form of fatty liver disease with moderate-to-advanced fibrosis, a meaningful development given how closely obesity and liver health are linked. The research landscape keeps moving.

The 7.2 mg question: what higher-dose semaglutide research found

A common follow-up question after reading the original STEP data is whether a higher dose changes things. The answer, from more recent semaglutide research, is yes, meaningfully. Trials at the 7.2 mg maintenance dose reported average weight losses of around 20.7% over 72 weeks, which begins to approach the results seen with tirzepatide at its highest maintenance dose. The MHRA approved a dedicated single-dose 7.2 mg pen on 14 April 2026 for adults with a BMI of 30 or above. The titration schedule remains the same: treatment begins at 0.25 mg and increases step by step, with a prescriber overseeing each progression.

It's worth being clear about what the 7.2 mg data shows and what it doesn't. These are still population averages from controlled trials with specific inclusion criteria. Individual responses depend on a range of factors including starting weight, metabolic health, consistency with lifestyle changes, and tolerance of the dose escalation. If you've seen the 20% figure cited and are wondering whether it represents a realistic outcome for you specifically, that is precisely the kind of question our clinical team works through at consultation.

For a broader look at what semaglutide research means in terms of how the medicine works at a chemical and pharmacological level, the semaglutide research and chemistry page goes into the mechanism in more detail. The short version: it binds GLP-1 receptors in the brain and gut, reducing appetite signals and slowing the rate at which the stomach empties, which is why many people find smaller portions feel satisfying in a way they didn't before.

What the research says about side effects and who experiences them

Clinical trials are also the source of the most reliable side-effect data, and the Wegovy research is candid here. Gastrointestinal effects (nausea, loose stools, constipation, reflux, burping) are the most common, particularly in the first weeks after starting or after a dose increase. In STEP 1, around 74% of participants on semaglutide reported at least one gastrointestinal event during the trial, compared with around 48% on placebo. Most were mild to moderate in severity and settled as the body adjusted.

One area where the research has generated new regulatory guidance is pancreatitis. The MHRA issued a Drug Safety Update in January 2026 confirming that acute pancreatitis is a known, if infrequent, risk with GLP-1 medicines. The practical signal from that update: severe, persistent stomach pain that radiates to the back, with or without vomiting, warrants urgent medical attention. The NHS medicines page for semaglutide covers the full side-effect profile in plain language and is updated as guidance changes.

Some people also notice unexpected effects that aren't widely covered in the main trial summaries. A small number report a metallic taste during treatment, for example. The trials weren't always designed to capture subtler experiences, which is one reason ongoing pharmacovigilance through the MHRA's Yellow Card scheme matters. Patients can report any suspected side effects at yellowcard.mhra.gov.uk.

How research eligibility differs from private prescription eligibility

Trial participants are selected to meet specific criteria, which means the research population isn't always identical to the people who might use the medicine in practice. In STEP 1, participants needed a BMI of at least 30 (or 27 with a qualifying condition) and no type 2 diabetes. The UK private prescription licence follows a similar framework: adults with a BMI of 30 or above, or 27 to 29.9 with at least one weight-related condition such as high blood pressure, high cholesterol, or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance.

NICE's NHS recommendation (TA875) is more restrictive: it applies within specialist weight management services, for a maximum of two years, for adults with a BMI of 35 or above plus at least one weight-related comorbidity. If you're weighing up the NHS route against a private pathway, the Wegovy overview page covers how both work. Those starting on the lower end of the dose range can find detailed guidance on Wegovy 1 mg, while people progressing further into treatment may find the Wegovy 2 mg page useful for understanding what to expect at that stage. If you want to understand what treatment options are available and whether Wegovy is relevant to your circumstances, the weight-loss treatments page sets out the landscape.

One practical note: consultations at nume happen on the same day as your order, Monday to Friday. If you're planning around a payday or a Monday-morning start, the process takes one working day from consultation to delivery once approved. There's no referral queue to join. When the research translates into a real clinical decision, our prescribers review each consultation personally. To see whether Wegovy is suitable for you, speak to our prescribers through a free consultation.